Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05451940 · ClinicalTrials.gov registry record · Phase 1
Hydroxyurea and EPO in Sickle Cell Disease
A Phase 1 study of Sickle Cell Disease and Anemia, Sickle Cell, sponsored by Julia Xu.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT05451940: Completed Phase 1 study of Sickle Cell Disease and Anemia, Sickle Cell, sponsored by Julia Xu.
NCT05451940 is a Phase 1 study of Sickle Cell Disease and Anemia, Sickle Cell that has completed, run by Julia Xu. The registered enrollment target is 17 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05451940, a Phase 1 study of Sickle Cell Disease and Anemia, Sickle Cell, has completed, sponsored by Julia Xu.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed study is a Phase 1/2 multi-center study evaluating the safety and efficacy of erythropoietin (EPO) in combination with hydroxyurea in the treatment of chronic anemia in patients with sickle cell disease (SCD).
Primary Outcome
Hb response is defined as a Hb increase of ≥ 1.0 g/dL at 12 weeks compared to baseline
Conditions Studied
Interventions
- DRUG Hydroxyurea
- DRUG Epoetin Alfa-BioSimilar
Study Locations (2)
Pennsylvania
- UPMC - Pittsburgh
Other
- Lagos University Teaching Hospital - Lagos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-05-25 |
| Est. Completion | 2025-02-27 |
| Phase | Phase 1 |
What the finished NCT05451940 record still lists
NCT05451940 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Hydroxyurea is the first listed.
NCT05451940 reports a single indexed study location in Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT05451940 about?
NCT05451940 is a clinical study titled "Hydroxyurea and EPO in Sickle Cell Disease". The proposed study is a Phase 1/2 multi-center study evaluating the safety and efficacy of erythropoietin (EPO) in combination with hydroxyurea in the treatment of chronic anemia in patients with sickle cell disease (SCD).
What is the current status of trial NCT05451940?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2023-05-25. Estimated completion is 2025-02-27.
What conditions does trial NCT05451940 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Anemia, Sickle Cell.
What interventions are being tested in trial NCT05451940?
The interventions under investigation include: Hydroxyurea (DRUG), Epoetin Alfa-BioSimilar (DRUG).
Who is sponsoring clinical trial NCT05451940?
This trial is sponsored by Julia Xu, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05451940 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05451940's enrollment target sits among peer trials
17 184th of 213 higher than 30 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
RECRUITING · Phase 1
-
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
RECRUITING · Phase 1
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI